OncoMatch

OncoMatch/Clinical Trials/NCT06238479

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Is NCT06238479 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies LY4101174 for metastatic solid tumor.

Phase 1RecruitingEli Lilly and CompanyNCT06238479Data as of May 2026

Treatment: LY4101174 — The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Urothelial Carcinoma

Triple-Negative Breast Cancer

Breast Carcinoma

Non-Small Cell Lung Carcinoma

Esophageal Carcinoma

Pancreatic Cancer

Ovarian Cancer

Cervical Cancer

Head and Neck Squamous Cell Carcinoma

Prostate Cancer

Disease stage

Required: Stage IV

Metastatic disease required

recurrent, advanced or metastatic solid tumors

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator

Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • AdventHealth Orlando · Orlando, Florida
  • Emory University · Atlanta, Georgia
  • Massachusetts General Hospital · Boston, Massachusetts
  • Washington University School of Medicine · St Louis, Missouri
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island · Mineola, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify